VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results highlight the potential for more targeted cancer therapies with reduced side effects.
The implications of these findings are significant for the oncology field, as ADCs have faced challenges with off-target toxicity. By enabling selective activation within tumor cells, BiTAC-ADC could broaden the therapeutic window for potent cytotoxic drugs. This approach may also allow for combination therapies that were previously limited by systemic toxicity.
VERAXA’s engagement at BIO 2026 underscores its strategy to advance its pipeline through partnerships. The company’s presence at the convention, a major industry event, provides a platform to showcase its technology to potential collaborators. The success of such collaborations could accelerate clinical development and bring BiTAC-based therapies to patients faster.
For more information on VERAXA Biotech and its latest updates, visit the company’s newsroom at https://ibn.fm/VRXA.
